The new service gives Houstonians a direct line to Hartford, the capital of Connecticut. Photo via aveloair.com

When it made its debut in June, soaring out of Houston's Hobby Airport, Avelo Airlines gave Houstonians another connection to the Northeast via a nonstop flight to New Haven, Connecticut (HVN) (also known as the Pizza Express). Now, the airline has announced another Northeast route that will begin this fall: Houston to Hartford's Bradley International Airport (BDL).

The airline will offer flights twice each week, on Mondays and Fridays, beginning November 15 on Boeing Next-Generation 737 aircraft. Fares will begin at $98. It cements Avelo's status as the only airline flying nonstop from Houston to Connecticut.

"We are excited to debut our second route from Houston," Avelo Airlines founder and CEO Andrew Levyin said in a statement. "I am very encouraged by the response to our inaugural service between Houston and New Haven, Connecticut, and I'm optimistic we'll see a positive response on both ends of this route, as well. We're already hearing from our customers how excited they are about the convenience, affordability, and reliability Avelo is introducing to Houston."

The new service gives Houstonians a direct line to Hartford, the capital of Connecticut. Its location means travelers can easily access the mountains and arts districts of Massachusetts' Berkshires, the rural beauty of western Connecticut, as well as small, picturesque towns just over the Connecticut line into New York. Hartford is also within striking distance to some of Connecticut's most popular attractions, including the Mark Twain House and Museum, performing arts centers, and more. It's also about an hour away from Providence, Rhode Island, making it a gateway to the Ocean State's beaches and attractions in Newport and beyond.

"This addition provides even more options for travelers seeking convenient and affordable connections between Houston and the Northeast. Following the success of their Hobby Airport to Tweed-New Haven route, this new flight further strengthens Hobby Airport's position as a leading regional travel hub," said Jim Szczesniak, director of aviation for Houston airports.

Avelo Airlines ranked No. 1 in on-time performance and achieved the lowest flight cancellation rate in the industry during the first half of 2024, according to results reported by Anuvu, a leading aviation data services company.The low-cost carrier offers seat assignments for an additional fee, and reserves one-third of its cabin as seats with extra legroom.

Customers may also opt to pay extra for things like priority boarding, checked bags, carry-on overhead bags, and bringing a pet in the cabin. There are no extra fees to change or cancel reservations, and the airline automatically seats children under the age of 14 with an accompanying adult for no extra charge.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”